ARTICLE | Company News
Merck, DNAtrix deal
October 19, 2015 7:00 AM UTC
The companies partnered to conduct a Phase II trial combining DNX-2401 from DNAtrix and melanoma drug Keytruda pembrolizumab from Merck to treat recurrent glioblastoma. DNX-2401, a genetically modif...